Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8

Benzinga · 2d ago
Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.